ECC Evansville Cancer Center
Contact Us

What's the Protocol? the Evansville Cancer Center.

The Evansville Cancer Center was the first oncology practice in Evansville to be approved to participate in the Eastern Cooperative Oncology Group (ECOG).

ECOG has been one of the premier multi-center cancer clinical trials organizations in the United States since its inception in 1955.  "By affiliating with ECOG in 1998, our patients have the opportunity to locally participate in national cancer trials," states Ronald Ruszkowski, MD, hematologist/oncologist at the Evansville Cancer Center.

Many of ECOG's randomized trials have established standards of care in malignancies such as bladder, breast, colon, lymphoma, melanoma, and rectal cancer.  ECOG was among the first of the National Cancer Institute (NCI) funded cancer cooperative groups to recognize the value of community hospital participation in cancer clinical trials.

In the last 15 years, ECOG has built a network of more than 250 community affiliates working more than one-third of ECOG's accrual to clinical studies. While building its research trials,  ECOG's data management program has been a model often copied by multi-center clinical trial organizations in the United States, Australia, and Europe.

More recently, ECOG has built a strong program in research translating advance in the understanding of the cellular and molecular biology of cancer to diagnosis and to innovative therapies.  ECOG has established a solid research program in cancer prevention and the delivery of cancer treatment and supportive care.  ECOG clinical trials are approved, monitored, and reviewed by the National Cancer Institute and local Institutional Review Boards.  On-site audits for completeness and accuracy of data are conducted on a routine basis at all ECOG sites.

In addition to ECOG protocols, the Evansville Cancer Center participates in a multitude of national clinical trials sponsored by a variety of pharmaceutical companies.  These protocols maintain goals similar to ECOG as well as require stringent guidelines for accuracy and the monitoring of patient progress.

For additional information about ECOG or general information about clinical trials, please refer to the Eastern Cooperative Oncology Group's Web site at

Areas of Active Research Protocols at the Evansville Cancer Center:


E1100 - A Phase I/II trial of Herceptin and Iressa in patients with Metastatic breast cancer that overexpresses HER2/neu.

S9927 - Randomized trial of Post-Mastectomy Radiotherapy in Stage II breast cancer in women with 1-3 positive axillary nodes, Phase III

N9831 - Phase III trial of Doxorubicin and Cyclophosphamide followed by weekly Paclitaxel with or without Trastuzumab as Adjuvant treatment for women with HER-2 overexpressing or amplified node positive breast cancer.

MA21 - A phase III Adjuvant trial of CEF versus EC/T vs. AC/T for Pre and Post Menopausal women who have had potentially curative surgery for node positive or high risk node negative breast cancer.


E1496 - Phase III, Cyclophosphamide/Fludarabine vs. standard therapy followed by maintenance Anti-CD20 antibody in low grade lymphoma.


E1697 - Randomized study of 4 weeks high does IFN-Alpha 2b in Stage II-A Melanoma

Lung Cancer

KCI9932 - A multicenter Phase II study of Paclitaxel, Irinotecan and Carboplatin in Extensive Stage Small Cell Lung Cancer.

1839IL/0050 - An expanded access clinical program with Iressa for patients with Advanced Non-Small Cell Lung Cancer.


H3E-US-JMFE - Open-label study of ALIMTA in combination with Cisplatin for chemonaive patients with Malignant Pleural Mesothelioma.

  Copyright © Evansville Cancer Center  •  All Rights Reserved  •  Disclaimer  •  Privacy